MASAKI FUJITA
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Masaki Fujita is a Professor at Fukuoka University Hospital, Japan. His research focuses on pulmonary infections, interstitial lung diseases, and the interactions of mycobacterial pathogens within host cells. Notable recent publications include studies on Mycobacterium abscessus, COVID-19 complications related to autoimmune conditions, and the efficacy of transbronchial cryobiopsy in Japan.
Articles (39)
Year:
2026
Year:
2025
Background and Aims Pulmonary nontuberculous mycobacteria (NTM) infection and bronchiectasis are two distinct respiratory conditions, but bronchiectasis and pulmonary NTM infections are closely associated. NTM can cause bronchiectasis. However, bronchiectasis can create a favorable environment for NTM colonization and exacerbate the progression of NTM. Managing both conditions typically requires a comprehensive approach that addresses infection and the underlying structural lung damage. Methods To perform this review, the author retrieved and assessed relevant articles related to NTM and bronchiectasis that have been published to date from databases, including PubMed/MEDLINE, Scopus, and Google Scholar. Results In this review, the close relationship between pulmonary NTM and bronchiectasis is described from the viewpoints of diagnosis, epidemiology, Pseudomonas aeruginosa , host susceptibility, females and NTM, and treatment. Conclusion Timely diagnosis and management of NTM infections, especially in individuals with underlying risk factors, are essential to prevent disease progression and improve the quality of life of affected individuals.
Year:
2025
Year:
2025
Tarlatamab, a DLL3‐targeting bispecific T‐cell engager, is an emerging option for previously treated small‐cell lung cancer (SCLC). Pseudoprogression with tarlatamab is poorly defined and can mimic drug‐induced pneumonitis. A 77‐year‐old man with extensive‐stage SCLC developed fever and hypoxia by Day 3 after the first 1‐mg dose, with rapid tumour enlargement and diffuse left‐lung infiltrates. High‐dose methylprednisolone and tocilizumab produced prompt clinical and radiographic improvement; follow‐up imaging showed resolution of infiltrates and tumour regression below baseline, consistent with pseudoprogression. This case suggests a reversible, lung‐predominant immune reaction with acute peritumoral infiltration likely driven by T cells. We propose the provisional term ‘Immune Cell‐Associated Respiratory Syndrome (ICARS)’. We speculate that baseline carcinomatous lymphangitis may predispose to ICARS. Recognising ICARS may prevent misdiagnosis and avoid premature discontinuation of effective therapy.
Year:
2025
Supplementary Figure S3. PFS of irAE other than skin or endocrine disorders (A) PFS of irAE other than skin or endocrine disorders according to the onset (B) PFS of irAE other than skin or endocrine disorders according to the grade One event with undetermined grade was excluded from the analysis according to grade. Abbreviations: CI, confidence interval; HR, hazard ratio; irAE, immune-related adverse event; PFS, progression-free survival
Year:
2025
Supplementary Table S5. Association between grade ≥3 irAEs and predictors of ICI effect a Mann–Whitney U Test. b Patients who had progression within 4 or 6 weeks after the initiation of treatment were excluded. Abbreviations: CRP, C-reactive protein; ICI, immune checkpoint inhibitor; IHC, immunohistochemical; irAE, immune-related adverse event; NLR, neutrophil-to-lymphocyte ratio; PD-L1, programmed death ligand-1; Q, quartile; SD, standard deviation.
Year:
2025
Supplementary Table S6. Association between skin or endocrine disorder irAEs and predictors of ICI effect a Mann–Whitney U Test. b Patients who had progression within 4 or 6 weeks after the initiation of treatment were excluded. Abbreviations: CRP, C-reactive protein; ICI, immune checkpoint inhibitor; IHC, immunohistochemical; irAE, immune-related adverse event; NLR, neutrophil-to-lymphocyte ratio; PD-L1, programmed death ligand-1; Q, quartile; SD, standard deviation.
Year:
2025
Supplementary Figure S1. PFS according to the grade of irAE (A) 4 weeks landmark PFS of irAE according to the grade (B) 8 weeks landmark PFS of irAE according to the grade One event with undetermined grade was excluded from the analysis. Abbreviations: CI, confidence interval; HR, hazard ratio; irAE, immune-related adverse event; PFS, progression-free survival
Year:
2025
Supplementary Figure S2. PFS of irAE of skin or endocrine disorders (A) PFS of irAE of skin or endocrine disorders according to the onset (B) PFS of irAE of skin or endocrine disorders according to the grade One event with undetermined grade was excluded from the analysis according to grade. Abbreviations: CI, confidence interval; HR, hazard ratio; irAE, immune-related adverse event; PFS, progression-free survival
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2021
Year:
2020
Year:
2020
Year:
2020
Year:
2020
Year:
2020
Year:
2020
Collaborators (6)
Chiharu Yoshii
Clinical Professor
-
Kazuhiro Yatera
University of Occupational and Environmental Health Japan
Yusuke Kurihara
Associate Professor
Kurume University
Masanori Hisaoka
Professor and chairman
University of Occupational and Environmental Health Japan
Akinori Shimizu
Fukuoka University
Tetsuya Mitsudomi
Professor
Kindai University
Make your next move.
Prepare your application
Review drafts before you send them.